Cramer: ‘I’m more nervous than I was before’ about coronavirus economic risks after Fed rate cut

Small Business

Jim Cramer

Adam Jeffery | CNBC

CNBC’s Jim Cramer said that the Federal Reserve‘s emergency interest rate cut on Tuesday morning makes him more concerned about the possible economic risks from the coronavirus.

“It’s great that the Federal Reserve recognizes that there’s going to be weakness, but it makes me feel, wow, the weakness must be much more than I thought,” Cramer said on “Squawk on the Street.”

“I’m now nervous. I’m more nervous than I was before,” he added.

The move helps Wall Street but does little to convince consumers worried about catching the coronavirus to leave their homes and spend their money, Cramer said.

Stock trading around the Fed’s surprise rate cut of 0.5% saw the Dow Jones Industrial Average swing from down over 350 points to up over 350 points. The Dow then flop-flopped between losses and gains.

The rate cut puts the fed funds target between 1%-1.25%. The Fed reduced rates in three 0.25% moves last year.

Hopes for a Fed cut rate sparked a powerful rally Monday. The Dow soared nearly 1,300 points or 5% in its biggest percent-gain since March 2009, reclaiming a big chunk of last week’s largest weekly decline since the financial crisis.

The Fed’s emergency cut — the first since December 2008 — comes two weeks before the central bank’s regularly scheduled March monetary policy meeting and after an early Tuesday conference call among G-7 central bankers and finance leaders, which yielded a pledge “to use all appropriate policy tools to achieve strong, sustainable growth and safeguard against downside risks” from the coronavirus outbreak.

Articles You May Like

Fed leaves rates unchanged: What it means for credit cards, mortgages, auto loans and savings accounts
Social Security Misunderstandings That Cost People Money
NSW agents face $110,000 fines as underquoting crackdown ramps up
A ‘canary in the coal mine’: Measles resurgence exposes weaknesses in U.S. public health, experts say
Biotech stocks are surging. How investors can play the new drug innovation boom

Leave a Reply

Your email address will not be published. Required fields are marked *